Pfizer in Talks with Mylan to Merge its Off-Patent Drug Business 

 Pfizer in Talks with Mylan to Merge its Off-Patent Drug Business 

Pfizer in Talks with Mylan to Merge its Off-Patent Drug Business

Shots:

  • Pfizer plans to combine its off-patent drug business with Mylan with the formation of a new entity for the generic business. Post completion of the deal, Mylan will hold 40% of the shares and remaining will belong to Pfizer
  • The merger will boost the sales of therapies which slowed due to loss of patent protection and began facing lower-priced competition. Additionally, Pfizer would receive $12B in proceeds from a new sale of debt
  • Pfizer’s off-patent drug includes Lipitor cholesterol pills and Viagra (the male impotence drug), Mylan’s EpiPen is an auto-injector for injecting a measured dose of epinephrine used to treat anaphylaxis

Click here to­ read full press release/ article | Ref: The Wall Street Journal | Image: Emaze

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post